

August 02, 2025

The Listing Department
BSE Limited
Phiroze Jeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Outcome of Board meeting under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

In furtherance to our letter dated July 09, 2025, and pursuant to Regulation 30 and 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company, at their meeting held today i.e., August 02, 2025 approved/noted the following:

1. Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025 along with Limited Review Report received from the M/s B S R and Co., Chartered Accountants (Firm registration Number 128510W) Statutory Auditors of the Company.
2. Appointment of M/s M P R & Associates, Cost Accountant (Firm Registration No.: 000413) as Cost Auditor of the Company for the financial year 2025-26 and recommendation to shareholders for ratification of remuneration. Refer Annexure I for the details as per SEBI Master circular no. 5EBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
3. Appointment of M/s. R & A Associates (Firm Registration No. P1994AP011100) as the Secretarial Auditors of the Company for five years from FY 2025-26 to FY 2029-30, subject to approval of shareholders. Refer Annexure I for the details as per SEBI Master circular no. 5EBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
4. Allotment of 79,157 Equity Shares under the MedPlus Employees Stock Option Plan, 2021 ('ESOP,2021') to the eligible employees of the Company/ Group Company. The detailed disclosure as required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SBEB Regulations') is being sent separately. We hereby clarify that the said allotment of shares is not material in nature to the Company.



5. The Board has also approved the proposal to convene 19th Annual General Meeting (“AGM”) of the Company on Monday, September 15, 2025 through Video Conferencing / Other Audio Visual Means in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The Notice of the AGM shall be intimated separately.

The meeting commenced at 02:00 PM and concluded at 04:45 PM.

The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

Kindly take the same on records.

For MedPlus Health Services Limited



Manoj Kumar Srivastava
Company Secretary & Compliance Officer



Encl: a/a

2/8/2025

Disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Particulars	Secretarial Auditor - M/s. R & A Associates	Cost Auditor - M/s M P R & Associates
Reason for change	Re-appointment of M/s. R & A Associates (Firm Registration No. P1994AP011100) Practicing Company Secretary as Secretarial Auditors of the Company.	Ratification of remuneration to M/s. M P R & Associates, Cost Accountants (Firm Registration No.: 000413), Cost Auditors of the Company for the financial year 2025-26.
Date of appointment & term of appointment	Appointment in the Board Meeting held on August 02, 2025, for a period of five consecutive years from Financial Year 2025-26 to Financial Year 2029-30, subject to the approval of shareholders of the Company at the ensuing Annual General Meeting.	Appointment in the Board Meeting held on August 02, 2025, for Financial Year 2025-26, subject to ratification of remuneration by the shareholders of the Company at the ensuing Annual General Meeting.
Brief profile (in case of appointment)	M/s. R & A Associates is a Partnership firm established in 1996 to provide various professional services to the corporates, an integrated Corporate Secretarial offering One-Stop solution for all Corporate Compliances and Legal Requirements. R&A has been on the forefront of the Corporate Legal Services sector – advising, guiding and servicing companies in India and abroad.	M/s. M P R & Associates, Cost Accountants (Firm Registration No.: 000413), Cost Auditors of the Company established in the year 2012 based at Hyderabad provide costing, accounting, taxation and advisory services. They are dedicated professionals in the domain of Cost Audit, MIS - Product costing, stock audit & valuation, cost of production certificate, cost system designing and implementation etc. They have served across various industries and diverse verticals.



Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

10

Limited Review Report (Continued)

MedPlus Health Services Limited

7. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,603.10 million, total net profit after tax (before consolidation adjustments) of Rs. 9.59 million and total comprehensive income (before consolidation adjustments) of Rs. 9.59 million, for the quarter ended 30 June 2025, as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial results of 8 Subsidiaries which have not been reviewed, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 605.69 million, total net profit after tax (before consolidation adjustments) of Rs. 6.07 million and total comprehensive income (before consolidation adjustments) of Rs. 6.07 million, for the quarter ended 30 June 2025, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

Arpan Jain

Partner

Hyderabad

02 August 2025

Membership No.: 125710

UDIN:25125710BMOXXY1991

Limited Review Report (Continued)
MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of Entity	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	Nova Sud Pharmaceuticals Private Limited	Subsidiary
4	Wynclark Pharmaceuticals Private Limited	Subsidiary
5	Kalyani Meditimes Private Limited	Subsidiary
6	Clearancekart Private Limited	Subsidiary
7	Sai Sridhar Pharma Private Limited	Subsidiary
8	Venkata Krishna Enterprises Private Limited	Subsidiary
9	Shri Banashankari Pharma Private Limited	Subsidiary
10	Deccan Medisales Private Limited	Subsidiary
11	Sidson Pharma Distributors Private Limited	Subsidiary
12	MedPlus Insurance Brokers Private Limited	Subsidiary


D

MedPlus Health Services Limited
CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037
Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2025

(Rs. in Millions)

S. No.	Particulars	Quarter ended			Year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		Unaudited	refer note 3	Unaudited	Audited
	Income				
	Revenue from operations	15,426.34	15,096.09	14,888.25	61,360.53
	Other income	150.19	157.92	87.12	486.16
I	Total income	15,576.53	15,254.01	14,975.37	61,846.69
	Expenses				
	Cost of materials consumed	191.80	195.46	123.78	617.19
	Purchases of stock-in-trade	10,529.48	11,367.21	12,458.43	45,724.81
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	676.08	(476.30)	(986.52)	64.61
	Employee benefits expense	2,004.41	1,941.71	1,618.22	7,260.17
	Finance costs	273.65	268.41	246.58	1,025.86
	Depreciation and amortisation expense	656.18	642.09	600.30	2,498.43
	Other expenses	717.27	704.27	736.71	2,822.73
II	Total expenses	15,048.87	14,642.85	14,797.50	60,013.80
III	Profit before tax (I-II)	527.66	611.16	177.87	1,832.89
	Tax expense				
	- Current tax expense	143.92	126.89	60.44	479.49
	- Deferred tax benefit	(39.69)	(28.93)	(26.01)	(148.93)
IV	Total tax expense	104.23	97.96	34.43	330.56
V	Net Profit after tax (III-IV)	423.43	513.20	143.44	1,502.33
	Other Comprehensive Income (OCI)				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain on employee defined benefit plan	-	2.02	-	2.02
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.56)	-	(0.56)
VI	Other comprehensive income for the period/year, net of tax	-	1.46	-	1.46
VII	Total comprehensive income for the period/year (V+VI)	423.43	514.66	143.44	1,503.79
VIII	Profit for the period/year attributable to:				
	Shareholders of the Company	423.58	513.35	143.63	1,503.22
	Non-controlling interest	(0.15)	(0.15)	(0.19)	(0.89)
		423.43	513.20	143.44	1,502.33
IX	Total comprehensive income attributable to:				
	Shareholders of the Company	423.58	514.81	143.63	1,504.68
	Non-controlling interest	(0.15)	(0.15)	(0.19)	(0.89)
		423.43	514.66	143.44	1,503.79
X	Paid-up Capital				
	Equity Share Capital	239.49	239.39	239.09	239.39
XI	Other Equity				17,166.22
XII	Earnings per equity share (refer note 4)				
	Basic (In absolute Rs.)	3.54	4.32	1.20	12.57
	Diluted (In absolute Rs.)	3.53	4.30	1.20	12.52
XIII	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00




Handwritten signature or initials in blue ink.

Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter ended June 30, 2025

(Rs. In Millions)

Particulars	Quarter Ended			Year Ended
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
	Unaudited	refer note 3	Unaudited	Audited
1. Segment revenue				
a. Retail	15,121.19	14,811.57	14,643.58	60,268.86
b. Diagnostic services	302.90	280.83	242.43	1,081.07
c. Others	2.25	3.69	2.24	10.60
Revenue from operations	15,426.34	15,096.09	14,888.25	61,360.53
2. Segment results profit / (loss)				
a. Retail	449.54	551.57	195.29	1,759.71
b. Diagnostic services	0.77	(9.04)	(42.90)	(109.76)
c. Others	1.07	2.45	0.66	4.89
Total	451.38	544.98	153.05	1,654.84
Less: Unallocable Finance cost	(0.27)	(0.59)	-	(0.59)
Add: Unallocable other income	76.55	66.77	24.82	178.64
Total profit before tax	527.66	611.16	177.87	1,832.89
3. Segment assets				
a. Retail	26,783.08	26,994.85	27,602.18	26,994.85
b. Diagnostic services	1,427.40	1,444.98	1,478.32	1,444.98
c. Others	5.93	7.77	-	7.77
d. Unallocated	6,284.53	5,153.35	2,171.00	5,153.35
Total	34,500.94	33,600.95	31,251.50	33,600.95
4. Segment liabilities				
a. Retail	15,669.74	15,289.58	14,406.23	15,289.58
b. Diagnostic services	983.75	911.18	892.61	911.18
c. Others	1.57	1.20	5.54	1.20
Total	16,655.06	16,201.96	15,304.38	16,201.96



D B

Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 02, 2025. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2025	Unutilised amount as on June 30, 2025*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,117.63	448.53	669.10
Total	5,789.33	5,120.23	669.10

*The aforesaid unutilised proceeds of Rs. 669.10 million have been placed as fixed deposits with bank.

3. The consolidated figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
4. The earnings per equity share for the quarters are not annualised.





GMK

Handwritten initials in blue ink.

5. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited



G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097

Place: Hyderabad

Date: August 02, 2025



Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2025 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The merger of MHS Pharmaceuticals Private Limited ("transferor company") with the Company has been accounted for during the quarter ended 30 September 2024 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 14 August 2024. Amalgamation has been accounted for by the Company by restating the financial information in the Statement in respect of prior periods as if it had occurred from the beginning of the preceding period in the financial results as per the requirement of Indian Accounting Standard.

The corresponding figures for the quarter ended 30 June 2024 in so far it pertains to the transferor company and considered for restatement as mentioned above, have not been reviewed.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

B S R and Co

Limited Review Report (Continued)
MedPlus Health Services Limited

Our conclusion is not modified in respect of this matter.

For **B S R and Co**
Chartered Accountants
Firm's Registration No.:128510W



Arpan Jain

Partner

Hyderabad
02 August 2025


Membership No.: 125710
UDIN:25125710BMOXXZ8078

MedPlus Health Services Limited
CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037
Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2025

(Rs. in Millions)

S. No	Particulars	Quarter ended			Year ended
		June 30, 2025	March 31, 2025	June 30, 2024 (Restated) (Refer note 6)	March 31, 2025
		Unaudited	refer note 4	Unaudited	Audited
	Income				
	Revenue from operations	1,838.81	2,017.51	1,783.26	7,130.97
	Other income	26.45	26.51	18.40	89.35
I	Total income	1,865.26	2,044.02	1,801.66	7,220.32
	Expenses				
	Cost of materials consumed	191.80	195.48	123.77	616.18
	Purchases of stock-in-trade	1,175.20	1,371.99	1,265.24	4,860.25
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.98	(10.85)	2.14	(10.90)
	Employee benefits expense	122.64	119.98	112.30	472.20
	Finance costs	21.52	20.80	20.99	86.25
	Depreciation and amortisation expense	67.21	65.09	64.74	269.37
	Other expenses	105.13	102.41	96.39	415.25
II	Total expenses	1,688.48	1,864.90	1,685.57	6,708.60
III	Profit before tax (I-II)	176.78	179.12	116.09	511.72
	Tax expense				
	- Current tax expense	46.91	35.59	28.68	109.22
	- Deferred tax (benefit) / expense	(5.46)	3.71	(5.15)	(0.85)
IV	Total tax expense	41.45	39.30	23.53	108.37
V	Net Profit after tax (III-IV)	135.33	139.82	92.56	403.35
	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain on employee defined benefit plan	-	2.67	-	2.67
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.67)	-	(0.67)
VI	Other comprehensive income for the period / year, net of tax	-	2.00	-	2.00
VII	Total comprehensive income for the period / year (V+VI)	135.33	141.82	92.56	405.35
VIII	Paid-up capital				
	Equity share capital	239.49	239.39	239.09	239.39
IX	Other Equity				12,164.08
X	Earnings / (Loss) per equity share (refer note 5)				
	Basic (In absolute Rs.)	1.13	1.17	0.77	3.37
	Diluted (In absolute Rs.)	1.13	1.17	0.77	3.36
XI	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00



Handwritten initials/signature.

Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 02, 2025. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2025	Unutilised amount as on June 30, 2025*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,117.63	448.53	669.10
Total	5,789.33	5,120.23	669.10

*The aforesaid unutilised proceeds of Rs. 669.10 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. The standalone figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
5. The earnings per equity share for the quarters are not annualised.



A handwritten signature in blue ink, located at the bottom left corner of the page.

6. On January 10, 2023, the Board of Directors of MedPlus Health Services Limited approved the Scheme of Amalgamation ('the Scheme') u/s 230 to 232 of the Companies Act, 2013, between MedPlus Health Services Limited ('the transferee Company') and MHS Pharmaceuticals Private Limited ('the transferor Company') with an appointed date of April 1, 2023. The Scheme has been approved by the National Company Law Tribunal (NCLT) Hyderabad bench, vide their order dated August 14, 2024 and a certified copy has been filed by the Company with the Registrar of Companies, Hyderabad, Telangana, on September 2, 2024.

The appointed date as per the NCLT approved Scheme is April 1, 2023, which is the same as the beginning of the preceding period in the standalone financial results and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 "Business Combinations". Accordingly, the amounts relating to the quarter ended June 30, 2024 shown in the statement, have been restated after recognizing the effect of the Scheme as above.

Impact of the Scheme on the statement of standalone results INR in millions

Sl. No	Particulars	Corresponding 3 Months ended June 30, 2024
I	Total income	0.04
II	Total expenses	1.98
III	Profit/(loss) before tax (I- II)	(1.94)
IV	Tax (benefit)/ expense	-
V	Profit/(loss) after tax (III - IV)	(1.94)
VI	Earnings per equity share (face value of Rs. 2/- each)	
	(a) Basic (Rs.)	(0.00)
	(b) Diluted (Rs.)	(0.00)

7. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited



G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097

Place: Hyderabad

Date: August 02, 2025